Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24481136 | 1.00 | HRH3 (0.37) | HRH3TLR9TLR8TLR7MEN1 | |
| SCHEMBL26143653 | 0.89 | HRH3 (0.36) | HRH3TLR9TLR8TLR7L3MBTL1 | |
| SCHEMBL178291 | 0.88 | HRH3 (0.43) | HRH3 | |
| SCHEMBL24941981 | 0.85 | OPRL1 (0.43) | HRH3TLR9TLR8TLR7L3MBTL1 | |
| SCHEMBL24827928 | 0.85 | HRH3 (0.34) | HRH3TLR9TLR8TLR7L3MBTL1 | |
| SCHEMBL22302355 | 0.85 | HRH3 (0.31) | HRH3MEN1KMT2A | |
| SCHEMBL27131232 | 0.85 | MEN1 (0.42) | HRH3MEN1KMT2AKDM4ETSHR | |
| SCHEMBL25046319 | 0.85 | MEN1 (0.42) | HRH3MEN1KMT2AKDM4ETSHR | |
| SCHEMBL24838821 | 0.83 | HRH3 (0.36) | HRH3TLR9TLR8TLR7L3MBTL1 | |
| SCHEMBL22306136 | 0.83 | HRH3 (0.36) | HRH3TLR9TLR8TLR7L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147385-A1 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147385-A1 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | TEK, KDR, LIPG | HRH3 4015/4885TLR9 2201/4885TLR8 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.